Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Παρασκευή 4 Σεπτεμβρίου 2015

! ORL via Alexandros G.Sfakianakis on Inoreader: Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients

! ORL via Alexandros G.Sfakianakis on Inoreader
 
Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients
Sep 4th 2015, 15:01, by Tawee Tanvetyanon, Kate Fisher, Jimmy Caudell, Kristen Otto, Tapan Padhya, Andy Trotti

Abstract

Background

The majority of patients with locally advanced salivary gland carcinoma will die of the disease even after curative surgery. Few studies on adjuvant therapy have been conducted. In this study, we compared adjuvant chemoradiotherapy (CRT) with adjuvant radiotherapy among the older patient population.

Methods

Surveillance, Epidemiology, and End Results (SEER)-Medicare database (1992–2009) was analyzed. Eligible cases were those receiving curative surgery followed by adjuvant therapy. Outcomes were overall survival and toxicity.

Results

Analyses included 741 patients: 641 patients (86.5%) received adjuvant radiotherapy and 100 (13.5%) received adjuvant CRT. The median overall survival was 41.0 months with adjuvant radiotherapy and 24 months with CRT. Both multivariable and propensity score-adjusted analyses indicated that adjuvant CRT was associated with an increased mortality (hazard ratio [HR]: 1.39; 95% confidence interval [CI]: 1.07–1.79 and HR: 1.49; 95% CI: 1.14–1.94, respectively). Toxicity rates were significantly higher in the CRT group.

Conclusion

Treatment with adjuvant CRT was associated with an increased mortality and toxicity when compared to adjuvant radiotherapy alone. © 2015 Wiley Periodicals, Inc. Head Neck, 2015

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου